T cell therapy is a type of cancer treatment that uses your own immune cells, specifically T cells, to find and destroy cancer. Doctors collect T cells from your body, enhance them in a laboratory so they’re better at recognizing tumors, then infuse them back into your bloodstream in large numbers. It’s one of the most significant advances in cancer treatment over the past decade, with some forms producing positive responses in more than 90% of patients with certain blood cancers.
There are several forms of T cell therapy, but they all share the same basic idea: supercharging your immune system’s natural ability to kill cancer cells. The differences come down to how the T cells are selected or modified before they’re returned to you.
Types of T Cell Therapy
The two main approaches are CAR T-cell therapy and TIL therapy. Each takes a different route to the same goal.
CAR T-cell therapy involves genetically modifying your T cells in a lab so they produce a synthetic protein called a chimeric antigen receptor (CAR) on their surface. Think of it as installing a new guidance system. That receptor is custom-designed to lock onto a specific protein found on the surface of your cancer cells. Once the modified T cells are infused back into your body, they circulate through your bloodstream, find cells displaying that protein, latch on, and kill them. The technology has gone through multiple generations of design. Early versions used a simple signaling mechanism, while newer versions include additional activation signals that make the T cells far more effective and longer-lasting.
TIL therapy (tumor-infiltrating lymphocyte therapy) takes a different approach. Instead of engineering new receptors, doctors extract T cells that have already migrated into your tumor. These cells have naturally identified the cancer as a threat but haven’t been able to overwhelm it on their own. In the lab, doctors test which of those T cells are best at recognizing tumor cells, grow them into vastly larger numbers, and then infuse them back. No genetic modification is needed because these T cells already know what to attack.
What T Cell Therapy Treats
T cell therapy has had its biggest successes against blood cancers. CAR T-cell products are currently approved to treat several types of lymphoma, certain forms of leukemia, and multiple myeloma. As of early 2025, one product (Breyanzi) received approval for marginal zone lymphoma, a relatively rare type, expanding the list of treatable cancers further.
Solid tumors, like those in the lung, breast, or colon, remain a much harder target. The problem is partly physical and partly biological. Solid tumors build a microenvironment around themselves that actively suppresses immune cells. T cells struggle to infiltrate the tumor, and even when they get inside, the tumor releases signals that exhaust them and shut down their killing ability. Cancer cells can also stop displaying the surface protein the T cells were designed to target, essentially going invisible. For breast cancer specifically, one commonly targeted protein appears in only about 60% of cases, making it difficult to develop a one-size-fits-all therapy. Clinical trials are underway for cancers of the liver, pancreas, stomach, colon, ovaries, and lungs, but these are still in earlier phases compared to blood cancer treatments.
How the Treatment Process Works
T cell therapy isn’t a single appointment. It’s a process that unfolds over weeks. The first step is leukapheresis, a procedure where blood is drawn from your body and run through a machine that separates out white blood cells (including T cells) before returning the rest of your blood. This typically takes a few hours.
Your collected cells are then shipped to a manufacturing facility, where the engineering or selection process happens. For CAR T-cell therapy, the cells are genetically modified, then grown into hundreds of millions of copies. This manufacturing step generally takes several weeks, though the exact timeline varies by product and facility. During this waiting period, many patients receive a short course of chemotherapy called “lymphodepletion” to prepare the body to accept the modified cells.
Once the cells are ready, they’re shipped back to your treatment center and infused through an IV. After infusion, you’ll typically stay in or near the hospital for at least a couple of weeks so your medical team can monitor for side effects. The modified T cells begin multiplying inside your body and hunting for cancer cells almost immediately.
Success Rates and Long-Term Outcomes
The initial response rates for CAR T-cell therapy in blood cancers are remarkable. More than 90% of patients with certain types of leukemia and lymphoma respond positively to treatment. Some patients achieve complete remission, meaning no detectable cancer remains.
The longer-term picture is more complicated. More than half of patients who respond will relapse within 12 months. A smaller group achieves durable remission lasting years. In one analysis of 82 pediatric leukemia patients from two early clinical trials launched in 2012, five patients remained in remission for more than eight years. Researchers are actively studying what makes those long-term survivors different, with early evidence pointing to specific characteristics of the T cells themselves that predict durability.
Side Effects and Risks
T cell therapy triggers the immune system powerfully, and that power comes with real risks. The two most significant side effects are cytokine release syndrome (CRS) and a neurological reaction called ICANS.
Cytokine release syndrome happens because activated T cells flood the body with inflammatory signals. Symptoms range from mild (fever, fatigue, muscle aches) to severe (dangerously low blood pressure requiring intensive care support). The severity is graded by how much medical intervention is needed to stabilize blood pressure and oxygen levels. Most patients experience some degree of CRS, but severe cases are less common and medical teams have become increasingly skilled at managing them.
ICANS (immune effector cell-associated neurotoxicity syndrome) can cause confusion, difficulty speaking, trouble concentrating, agitation, tremors, and in rare cases, seizures or brain swelling. These neurological symptoms typically appear during or after CRS resolves. Headaches are extremely common and don’t necessarily signal a serious neurological problem. Most ICANS symptoms are temporary and resolve with treatment, though their unpredictability is one reason patients are closely monitored in the hospital after infusion.
Cost of Treatment
T cell therapy is among the most expensive cancer treatments available. The list price for the therapy itself, not including hospitalization, monitoring, or management of side effects, runs between roughly $500,000 and $600,000 per patient. Kymriah, one of the earliest approved products, carries a list price of about $593,500. Yescarta, another widely used product, is priced at approximately $503,600. These figures represent wholesale acquisition costs and don’t account for potential insurance negotiations, rebates, or outcome-based payment arrangements that some manufacturers offer.
Total costs including hospital stays, the lymphodepletion chemotherapy, and side effect management can push the bill significantly higher. Insurance coverage varies, and many treatment centers have financial counselors to help navigate the process. The high price reflects the individualized nature of the therapy: each dose is manufactured from scratch using a single patient’s own cells.
Who Is Eligible
T cell therapy is not a first-line treatment. Current approvals are for patients whose cancer has returned after initial treatment or hasn’t responded to at least two previous lines of therapy. This means most people receiving T cell therapy have already been through standard chemotherapy, and in some cases a stem cell transplant, without lasting success.
Eligibility also depends on practical factors. Your T cells need to be healthy enough to survive collection and manufacturing. Patients who have received certain chemotherapy drugs need to wait weeks or even months before their cells can be collected, because some drugs suppress or damage T cells. For example, patients treated with certain chemotherapy combinations need to stop those drugs at least 12 weeks before cell collection to ensure adequate T cell quality. Your overall health and organ function matter too, since the side effects of treatment require a body that can tolerate significant immune activation.